Next 10 |
home / stock / exas / exas articles
U.S. stocks were lower, with the Dow Jones falling around 400 points on Tuesday. Shares of ChampionX Corporation (NASDAQ: CHX) rose sharply during ...
U.S. stocks were slightly higher, with the S&P 500 gaining around 0.1% on Thursday. Shares of REX American Resources Corporation (NYSE: REX) ro...
Investors pinned hopes on Nvidia Corp.’s (NASDAQ:NVDA) earnings to reinvigorate market momentum, and the AI leader delivered an impressive ...
On Tuesday, Cathie Wood-led Ark Invest made a significant purchase of Roku Inc (NASDAQ:ROKU) shares. This decision comes amidst a period of market ...
Exact Sciences Corporation (NASDAQ: EXAS) shares are trading higher Wednesday, and the stock has gained over 8% in the past month. Here's a loo...
U.S. stocks traded mixed, with the Dow Jones index falling around 50 points on Wednesday. Shares of The Toro Company (NYSE: TTC) rose sharply durin...
Ark Invest’s Zoom Trade: On Wednesday, Cathie Wood-led Ark Invest made a significant move by purchasing over $12 million worth of Zoom Video ...
Exact Sciences Corp (NASDAQ: EXAS) filed a patent infringement lawsuit against Geneoscopy in the U.S. District Court for the District of ...
Stocks experienced a modest surge amid the Federal Open Market Committee meeting Wednesday. The central bank is widely expected to leave interest r...
News, Short Squeeze, Breakout and More Instantly...
Exact Sciences Corporation Company Name:
EXAS Stock Symbol:
NASDAQ Market:
Exact Sciences Corporation Website:
2024-04-15 11:30:02 ET William Blair analyst issues OUTPERFORM recommendation for EXAS on April 15, 2024 10:21AM ET. The previous analyst recommendation was Outperform. EXAS was trading at $68.965 at issue of the analyst recommendation. The overall analyst consensus : BU...
Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer (CFO), effective May 15, 2024. Mr. Bloomer brings to Exact Sciences more than 15 years of finance and accounting experience. ...
First analysis from ASCEND-2 confirms high detection rates and specificity achieved with multi-biomarker approach in most aggressive cancers and those with no standard-of-care screening test 1 Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic t...